<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529241</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-15-1-01</org_study_id>
    <nct_id>NCT02529241</nct_id>
  </id_info>
  <brief_title>An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371</brief_title>
  <official_title>An Open-label, Single Dose, Parallel Design, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Oral Dosage Form of LCB01-0371 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate pharmacokinetics, safety and tolerability of LCB01-0371, LCB01-0371-B after a
      single oral dose in healthy male subjects.

      To investigate safety, tolerability of LCB01-0371 after a single oral dose in healthy male
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Single dose, Parallel design, Phase I Study to Investigate the
      Pharmacokinetics, Safety, and Tolerability of Oral dosage form of LCB01-0371 in Healthy Male
      Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: time to maximum concentration (Tmax)</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Event</measure>
    <time_frame>participants will be followed after hospital stay, an expected average of 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: LCB01-0371</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: LCB01-0371</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1:LCB01-0371</intervention_name>
    <description>Period:LCB01-0371 Tablet 400 mg
Period: LCB01-0371 Tablet 400 mg</description>
    <arm_group_label>Group 1: LCB01-0371</arm_group_label>
    <arm_group_label>Group 2: LCB01-0371</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2:LCB01-0371</intervention_name>
    <description>Period:LCB01-0371 Tablet 800 mg
Period: LCB01-0371 Tablet 1200 mg</description>
    <arm_group_label>Group 1: LCB01-0371</arm_group_label>
    <arm_group_label>Group 2: LCB01-0371</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male between 20 and 40 years of age at the time of screening

          2. Agree to continue to use a medically reliable dual contraception and not to donate
             sperm in this protocol for the duration of the study and for 28 days after last dose
             of investigational product

          3. Capable of giving written informed consent, willing to participate in this clinical
             trial, and willing to comply with all study requirements

        Exclusion Criteria:

          1. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer)
             within 6 months possibly affecting absorption of clinical trial drugs, or history of
             surgery (except simple appendectomy and herniotomy)

          2. History of hypersensitivity reaction or history of clinically significant
             hypersensitivity reaction to LCB01-0371 or same class of the study drugs (linezolid)
             or other drugs including aspirin and antibiotics

          3. History of clinically significant disease such as allergic or anaphylactic reaction to
             drug, cardiovascular, peripheral vascular system, skin, mucous membrane, eye,
             otorhinolaryngologic system, respiratory, musculoskeletal, infection disease,
             Gastrointestinal system , liver, biliary system, endocrine, kidney, urogenital system,
             nervous system, psychiatric system, blood dyscrasia, tumor, fracture, problem(s)

          4. blood donation and transfusion within 60 days prior to screening visit

          5. Treatment with an other investigational product or Participation in other
             bioequivalence test within 90 days prior to screening visit

          6. Use medication which expected to influence in this study within 30 days prior to
             screening visit

          7. smokers over 10 cigarettes per day within 30 days prior to screening visit or unable
             to stop smoking in this protocol for the duration of the study from first dose of
             investigational product

          8. drinkers over 3 glasses alcohol drink per week within 30 days prior to screening visit
             or unable to stop drinking in this protocol for the duration of the study from first
             dose of investigational product

          9. positive result at urine drug screening test or urine nicotine test at screening visit

         10. positive result at serum test(hepatitis B, hepatitis C, HIV, syphilis) at screening
             visit

         11. corrected QT interval &gt;450 msec or significant abnormalities on screening ECG

         12. other: Patients considered unable perform for the study by the investigator concerning
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

